GSK plc American Depositary Shares (Each representing two Ordinary Shares) GSK

GSK plc es una empresa global de biotecnología. La Compañía fabrica vacunas y medicamentos especializados para prevenir y tratar enfermedades. Sus segmentos incluyen Operaciones Comerciales e Investigación y Desarrollo. Desarrolla medicamentos contra el cáncer para pacientes, incluyendo cáncer de ovario, cáncer de endometrio y mieloma múltiple. Ha desarrollado un nuevo tratamiento con anticuerpos monoclonales para COVID-19. Sus áreas de productos incluyen vacunas, medicamentos especializados y medicamentos generales. Su cartera de vacunas incluye más de 20 vacunas que ayudan a proteger a las personas de una variedad de enfermedades e infecciones a lo largo de sus vidas. Sus medicamentos especializados incluyen medicamentos para condiciones inmunomediadas, incluyendo la enfermedad autoinmune crónica lupus, enfermedades respiratorias y el virus de inmunodeficiencia humana (VIH). Sus medicamentos generales incluyen medicamentos inhalados para el asma y la enfermedad pulmonar obstructiva crónica (EPOC), antibióticos y medicamentos para enfermedades de la piel. Tiene una red global de aproximadamente 12 sitios de fabricación de vacunas.

Con 21 acciones de GSK (USD 977,23) habrías recibido USD 38,01 en dividendos en los últimos 12 meses.

GSK hizo una agrupación de acciones (split inverso) de 4:5 el 19 de julio de 2022: cada 5 acciones se juntaron en 4. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 30 sept

  Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies

  Hatteras Venture Partners appointed Sir Andrew Witty as Chairman and Dr. Ned Sharpless as Managing Director of Hatteras Discovery Innovation. The firm announced the first closing of Hatteras Opportunity Fund II targeting $100 million, bringing total capital under management to over $1 billion. The new Discovery strategy aims to replicate the success of the original 2012 initiative that seeded 11 companies and contributed to two FDA-approved medicines.

  

• Zacks Investment Research 29 sept

  GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?

  GSK and Sanofi, two major European pharmaceutical companies, are compared across growth drivers, pipelines, and valuations. GSK shows strong specialty medicines growth (14% in H1 2026) with expanding oncology and HIV franchises, while Sanofi benefits from blockbuster Dupixent sales (up 28.6%) and stronger near-term earnings growth. Despite both holding Hold ratings, Sanofi appears better positioned due to superior earnings growth outlook, favorable valuation metrics, and positive estimate revisions, though it faces vaccine sales headwinds and heavy Dupixent reliance.

  

• GlobeNewswire Inc. 27 sept

  HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

  HUTCHMED has initiated a Phase Ia global clinical trial of HMPL-A830, a first-in-class antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody for treating solid tumors. The first patient was dosed on September 24, 2026. HUTCHMED entered an exclusive development and licensing agreement with GSK on September 3, 2026, granting GSK worldwide rights (excluding Greater China) for development and commercialization.

  

• GlobeNewswire Inc. 17 sept

  Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

  The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

  

• GlobeNewswire Inc. 16 sept

  Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

  Over 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.